Last reviewed · How we verify
NCT04957238: ARBORéa
Physical Restraints in Intensive Care Unit Patients
NA trial testing ARBORea decision-making tool in Critically Ill in 4,000 participants. Status unknown.
27 November 2025
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 4,000 |
| Start date | 18 May 2022 |
| Primary completion | 27 November 2025 |
| Estimated completion | 27 February 2026 |
| Sites | 20 locations across France |
Drugs / interventions tested
- ARBORea decision-making tool
Conditions studied
- Critically Ill — all drugs for Critically Ill →
- Intensive Care Unit Delirium — all drugs for Intensive Care Unit Delirium →
- Delirium Confusional State — all drugs for Delirium Confusional State →
- Agitation,Psychomotor — all drugs for Agitation,Psychomotor →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
18 and older, any sex, with Critically Ill or Intensive Care Unit Delirium. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The use of physical restraints is common practice in Intensive Care Units (ICU). This medically prescribed procedure requires full attention of medical and paramedical teams for its implementation, monitoring and ending, as a major restriction of patients' individual freedom. French highest authority for health has defined, for geriatrics and psychiatric units, ten criteria of good practice for physical restraints' use. Routine practice reports critically ill patients' safety as main reason of use. This decision, often left to the sole discretion of nurses, varies according to their own representation of this risk, and depends on several factors: seniority in ICU, nurse to patient ratio and personal workload. In order to reduce practices subjectivity and heterogeneity, we have developed a decision-making tool for physical restraints implementation. This tool is based on objective scales used on a daily basis concerning neurological status (Richmond Agitation-Sedation Scale (RASS) and Confusion Assessment Method for the ICU (CAM-ICU)). Disorientation or delirium can lead to severe incidents by promoting accidental removing of important devices such as arterial of venous line, drains among others. However, physical restraints are recognized as a major cause of delirium and agitation. Critically ill patients require rigorous evaluation of organ dysfunctions necessitating adequate invasive equipments, with associated risks of unexpected removal or alteration. Such events could urge caregivers to use physical restraints. Based on recent literature, about a third of ICU patients are restrained, and accidental deconditioning is mainly observed within these particular patients. In addition, three categories of patients have been defined according to the invasive nature of their equipment and therefore according to the risk associated with an unexpected withdrawal. Finally, presence of patient's family and their adherence to its surveillance were also implemented into the tool. Main study objective is to jointly investigate effectiveness and tolerance of a decision-making tool guiding physical restraints use in ICU patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Stepped wedge cluster randomised controlled trial to assess the impact of a decision support tool for physical restraint use in intensive care units (ARBORea Study): a study protocol.
Vidal P, Lambert C, Pereira B, Martinez R, et al · · 2025 · cited 1× · PMID 40398949 · DOI 10.1136/bmjopen-2024-085674
Verify or expand the search:
- PubMed search for NCT04957238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critically Ill
Currently open trials in the same condition.
- NCT07222007 — Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients · recruiting
- NCT07143695 — Parasternal Intercostal Muscle Thickening as an Additive Weaning Criterion · NA · recruiting
- NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
- NCT05055830 — Opportunistic PK/PD Trial in Critically Ill Children (OPTIC) · recruiting
- NCT05112328 — The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding · NA · recruiting
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04957238 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04957238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing